ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,564.41
1.08%
US Tech 100
19,286.40
-0.03%
Dow Jones
40,415.44
0.32%
Brent Oil
81.415
-0.12%
Bitcoin
66,889.33
-1.06%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU

  6. OSE Immunotherapeutics (OSE) Quote

OSE Immunotherapeutics

OSE Immunotherapeutics (OSE)

EU
6.58
0.12
( 1.86% )
Updated: 06:26:55
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
6.58
Bid
6.54
Ask
6.58
Volume
14,665
6.49 Day's Range 6.59
2.705 52 Week Range 8.63
Market Cap
140.62M
Previous Close
6.46
Open
6.54
Last Trade
10
@
6.58
Last Trade Time
06:26:55
Financial Volume
-
VWAP
-
Average Volume (3m)
199,336
Shares Outstanding
21,767,777
Dividend Yield
-
PE Ratio
-6.23
Earnings Per Share (EPS)
-1.06
Revenue
2.23M
Net Profit
-23M

About OSE Immunotherapeutics

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Website
www.ose-immuno.com
Headquarters
Nantes, Loire-atlantique, Fra
Founded
1970
OSE Immunotherapeutics is listed in the Coml Physical, Biologcl Resh sector of the Euronext with ticker OSE. The last closing price for OSE Immunotherapeutics was 6.46 €. Over the last year, OSE Immunotherapeutics shares have traded in a share price range of 2.705 € to 8.63 €.

OSE Immunotherapeutics currently has 21,767,777 shares outstanding. The market capitalization of OSE Immunotherapeutics is 140.62 € million. OSE Immunotherapeutics has a price to earnings ratio (PE ratio) of -6.23.

OSE Latest News

More News

OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer

OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer OSE Immunotherapeutics et...

July 03 2024
GlobeNewswire Inc.

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Boehringer Ingelheim and OSE Immunotherapeutics...

July 03 2024
GlobeNewswire Inc.

Informations relatives au nombre total de droits de vote et d’actions composant le capital

Informations relatives au nombre total de droits de vote et d’actions composant le capital Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes...

July 02 2024
GlobeNewswire Inc.

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ 

OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’  OSE Immunotherapeutics...

July 01 2024
GlobeNewswire Inc.

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T

OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T OSE Immunotherapeutics annonce un accord commercial et de partage...

June 24 2024
GlobeNewswire Inc.

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)

OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San...

June 20 2024
GlobeNewswire Inc.

OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société

OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société OSE...

June 19 2024
GlobeNewswire Inc.

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse OSE Immunotherapeutics...

June 12 2024
GlobeNewswire Inc.

Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules

Webinaire KOL Investisseurs d’OSE Immunotherapeutics : le paysage thérapeutique et les besoins médicaux non satisfaits dans le cancer du poumon non à petites cellules Webinaire KOL...

June 12 2024
GlobeNewswire Inc.

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant OSE Immunotherapeutics and Nantes University...

June 05 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.41-5.865522174546.996.996.46966106.59436766DE
40.559.121061359876.037.275.371396296.42787254DE
121.0218.3453237415.568.635.371993366.95483247DE
262.7973.61477572563.798.633.1151645886.07098283DE
523.1390.72463768123.458.632.7051845115.36525132DE
156-2.22-25.22727272738.813.682.705920086.20026236DE
2602.8375.46666666673.7515.82.705849487.20145534DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NMHINatures Miracle Holding Inc
$ 0.8398
(139.94%)
7.95M
WRNTWarrantee Inc
$ 0.5991
(105.88%)
8.06M
FEIMFrequency Electronics Inc
$ 13.75
(36.14%)
115.83k
TUSKMammoth Energy Services Inc
$ 4.50
(28.57%)
65.83k
LGHLWLion Group Holding Ltd
$ 0.0091
(28.17%)
4.5k
RNAZTransCode Therapeutics Inc
$ 0.3274
(-58.69%)
418.09k
MIRAMIRA Pharmaceuticals Inc
$ 3.49
(-30.34%)
943.44k
CMAXCareMax Inc
$ 3.82
(-26.40%)
323.75k
BREABrera Holdings PLC
$ 0.5754
(-21.94%)
1.74M
NUKKNukkleus Inc
$ 0.3998
(-19.72%)
147.77k
NMHINatures Miracle Holding Inc
$ 0.7961
(127.46%)
7.44M
WRNTWarrantee Inc
$ 0.6165
(111.86%)
6.4M
LIFWMSP Recovery Inc
$ 0.553
(9.14%)
4.19M
BREABrera Holdings PLC
$ 0.578
(-21.58%)
1.73M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 14.52
(1.61%)
1.42M

Discussion

View Full Feed
VDB1 VDB1 2 minutes ago
Lightwave Logic's choice to bring Le Maitre on board underscores the company's commitment to leadership with deep industry knowledge.

In other recent news, Lightwave Logic has made significant strides in its commercial strategy and technological advancements. The company has emphas
LWLG
Nerd Beautiful Nerd Beautiful 2 minutes ago
Two happy things I just remembered. Tony said there were some good things in the works earlier this year. I just rediscovered the ignore this member button
LQMT
goldslacker2023 goldslacker2023 3 minutes ago
Words of wisdom; Be careful to not lock the knees. Better balance in the event there's ever a pendulum swing in life. Is it just me or have you noticed any volume lately in the OTC? Tread heavy. New tires but it cost me. You play you pay. Tallyho!
GNCP
TRUSTUNITS1000000 TRUSTUNITS1000000 3 minutes ago
TGGI huge company in the making, maybe
TGGI
WooptdooU WooptdooU 3 minutes ago
Maybe this guy will help get the ceo and cob into separate bodies. Right now you have a KNOWN MISGUIDER acting as both! This , ahem, "expert witness" corporate welfarist has groomed his family long enough off the back of capitalism...
LWLG
Awl416 Awl416 3 minutes ago
New lows
DRMA
Awl416 Awl416 3 minutes ago
Ready?
ZEO
TRUSTUNITS1000000 TRUSTUNITS1000000 4 minutes ago
EEENF can’t go wrong at these prices
EEENF
abrooklyn abrooklyn 5 minutes ago
https://pr.tsmc.com/system/files/newspdf/attachment/09349f4b044016a40b284519b3c86005b578749f/2Q24%20%28E%29_with%20guidance_final_wmn.pdf

TSMC Reports Second Quarter EPS of NT$9.56
HSINCHU, Taiwan, R.O.C., Jul. 18, 2024 -- TSMC (TWSE: 2330, NYSE: TSM) today
announced con
TSM
Pennies_Envy Pennies_Envy 5 minutes ago
Nothing really new in the q&a but glad they are posting
HIRU
TRUSTUNITS1000000 TRUSTUNITS1000000 5 minutes ago
Don’t let the shares outstanding scare you, this can run quickly
EEENF
primecomm primecomm 6 minutes ago
Good Morning $RNVA
RNVA
TRUSTUNITS1000000 TRUSTUNITS1000000 6 minutes ago
Management is going to make us happy $$$$$$$
EEENF
LVerstee LVerstee 6 minutes ago
Thanks for the explanation. What you’re describing sounds like a potential pump-and-dump scheme. Doubling profits every 15 days and constantly increasing yields seems pretty unrealistic. What study or source is this based on? Claims that the token is "too cheap" and predictions of it reaching $100 s
ITUP
HD2001 HD2001 6 minutes ago
Lies audits, QB listening ,funding , many acquisitions, filing dates, revenue, profits, there's zero chance of xalles being truthful.
XALL
MightyX MightyX 7 minutes ago
Retail-trader-group-fraud lost nearly half its OS interest overnight
TPTW
mfaphoto mfaphoto 7 minutes ago
But the fee to buy them is $6.95, so they will cost you about 4 cents each.
NSAV
Awl416 Awl416 7 minutes ago
Boy that “Seasoned” Investment Banker Dan McClory sure getting crushed here
BREA
LetGoodTimesRoll LetGoodTimesRoll 8 minutes ago
The MAN SAID,

"Moving forward

We began 2024 with positive operational momentum and seek to build on recent achievements to: (i) further expand our healthcare services offerings in the communities we serve, (ii) consider options to reopen or create value from our closed
RNVA
abrooklyn abrooklyn 9 minutes ago
Tyler Technologies Named to America’s Best Midsize Companies List

Source: Business Wire
TIME recognizes Tyler on its inaugural 2024 list

Tyler Technologies, Inc. (NYSE: TYL) was recently recognized on the inaugural list of TIME’s “America’s Best Midsize Companies
TYL
Monksdream Monksdream 9 minutes ago
MIRA yesterday, WRNT this morning’s screamer
WRNT
Monksdream Monksdream 9 minutes ago
MIRA yesterday, WRNT this morning’s screamer
WRNT
Awl416 Awl416 10 minutes ago
LOL
WRNT
jrsh jrsh 12 minutes ago
Why does a company with almost NO BUSINESS AT ALL needs multiple directors in the first place ??? Lol

Oh wait, i forgot, it's because they can draw nice salaties even when achieving absolutely nothing!!!
HMNU

Your Recent History

EU
OSE
OSE Immunotherapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved